INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42201, 25693, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42202, 29861, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42203, 30601, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42204, 30602, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42205, 1599, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42206, 6775, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42207, 7745, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42208, 7974, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42209, 7975, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42210, 8311, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42211, 9025, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42212, 13384, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42213, 13629, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42214, 13630, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42215, 17105, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42216, 17106, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42217, 17652, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42218, 17653, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42219, 19328, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42220, 19361, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42221, 19362, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42222, 22877, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42223, 23654, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42224, 25693, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42225, 29861, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42226, 30601, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42227, 30602, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42228, 14351, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42229, 14352, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42230, 14354, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42231, 14355, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42232, 14356, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42233, 14357, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42234, 14358, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42235, 14359, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42236, 14360, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42237, 14361, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42238, 14351, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42239, 14352, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42240, 14354, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42241, 14355, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42242, 14356, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42243, 14357, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42244, 14358, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42245, 14359, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42246, 14360, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42247, 14361, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42248, 14351, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42249, 14352, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42250, 14354, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42251, 14355, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42252, 14356, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42253, 14357, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42254, 14358, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42255, 14359, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42256, 14360, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42257, 14361, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42258, 14351, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42259, 14352, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42260, 14354, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42261, 14355, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42262, 14356, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42263, 14357, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42264, 14358, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42265, 14359, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42266, 14360, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42267, 14361, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42268, 19378, 'Dalteparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42269, 19379, 'Dalteparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42270, 19378, 'Dalteparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42271, 19379, 'Dalteparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42272, 19378, 'Dalteparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42273, 19379, 'Dalteparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42274, 19378, 'Dalteparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42275, 19379, 'Dalteparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42276, 19378, 'Dalteparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42277, 19379, 'Dalteparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42278, 19378, 'Dalteparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42279, 19379, 'Dalteparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42280, 19378, 'Dalteparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42281, 19379, 'Dalteparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42282, 19378, 'Dalteparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42283, 19379, 'Dalteparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42284, 19378, 'Dalteparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42285, 19379, 'Dalteparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42286, 19378, 'Dalteparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42287, 19379, 'Dalteparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42288, 4352, 'Darolutamide', 'Hepatic Insufficiency', 'Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose).  No dose reduction is needed for patients with mild hepatic impairment.  The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42289, 4352, 'Darolutamide', 'Kidney Diseases', 'Patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2) who are not receiving hemodialysis have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose).  No dose reduction is needed for patients with mild or moderate renal impairment.  The effect of end stage renal disease (eGFR <15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42290, 3326, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42291, 5227, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42292, 12978, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42293, 3326, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42294, 5227, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42295, 12978, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42296, 3296, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42297, 3297, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42298, 3315, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42299, 17094, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42300, 17137, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '', 'DDInter', 0);
